PR98689

BIORCHESTRA announces that BMD-001 reduces Amyloid-beta; and Tau in non-human primate animal model of Alzheimer's Disease at the RNA Leaders USA Conference in Boston

BOSTON, Nov. 8, 2022 /PRNewswire=KYODO JBN/ --

Dr. Branden Ryu, CEO and Founder of BIORCHESTRA Ltd. (S. Korea), was a featured

speaker at a plenary session of the RNA Leaders Congress USA in Boston, MA, on

October 18th, 2022. Dr Ryu focused on the new efficacy data of their leading

compound, BMD-001, derived from studies in non-human primates that demonstrated

clearance of both amyloid-beta and tau pathological proteins.

RNA Leaders USA focuses on the scientific, clinical and commercial development

of RNA therapeutics and vaccines. The meeting brings together the most senior

executives to deliver updates from across the full RNA landscape (RNAi,

antisense technologies, small molecule targeting, mRNA, and more). In addition

to Dr. Branden Ryu, other senior leaders present represented Ionis, Alnylam,

Sanofi, Bayer, Eli Lilly, Astra Zeneca, Roche, and a number of emerging biotech

companies. A particular focus of the meeting was the challenge of delivering

RNA-based therapeutics to specific organs, in particular to the brain.

In his talk, Dr Ryu presented data generated in collaboration with the National

Primate Research Center of the Korea Research Institute of Bioscience and

Biotechnology. Using a primate disease-induction model of Alzheimer's disease,

BIORCHESTRA was able to demonstrate brain target (microRNA-485-3p) engagement

by intravenously administered BMD-001, and subsequent clearance of both

amyloid-beta and tau proteins. Thus, it was again confirmed, this time using a

primate model of Alzheimer's disease, that BIORCHESTRA's Drug Delivery System

(BDDS™) penetrates the blood brain barrier and delivers to the relevant cell

types to ameliorate neurodegenerative changes. The data further demonstrated

widespread distribution of BMD-001 into the cortex, bulbar and cord regions.

In the conference presentation, Dr Ryu stated: "The encouraging results of this

experiment are that the intravenous injection of our BDDS™ can deliver drugs

broadly in the CNS: to the frontal lobe, thalamus, hypothalamus, striatum and

hippocampus, as well as to the spine." He further added: "This experiment

confirmed the biodistribution data previously established in the non-human

primate but, in addition, the efficacy of BMD-001 established in smaller animal

disease models is now confirmed with an efficacy read-out in the non-human

primate. This gives us confidence that our brain delivery platform is scalable

to the human context", he concluded.

[about BIORCHESTRA]

BIORCHESTRA is a South Korean-based biotechnology company focused on the

treatment of neurodegenerative disorders such as Alzheimer's Disease and

amyotrophic lateral sclerosis (ALS), or Lou Gehrig's Disease. BIORCHESTRA was

founded in 2016 by Dr. Branden Ryu based on his doctoral and postdoctoral work

in this field.

The most advanced drugs in the BIORCHESTRA pipeline focus on neurodegenerative

diseases and target a key regulator of neuroinflammation and neurodegeneration,

microRNA-485-3p. Other programs focus on CNS oncology and genetic brain

disease, such as Huntington's Disease.

BIORCHESTRA remains privately funded and has recently opened an R&D Center and

GMP Manufacturing facility in its home city of Daejeon, South Korea. In

addition to Daejeon, South Korea, BIORCHESTRA also has offices in One Kendall,

Cambridge, MA, USA.

NYC Innovation QuickFire Challenge on Neuroscience | Johnson & Johnson

Innovation (jnjinnovation.com)

https://www.skbp.com/eng/news/view.do?boardCode=BDCD0001&boardSeq=546¤tPage=1&search=biorchestra

SOURCE BIORCHESTRA

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=433296